Amitinib is a domestic medicine, and oxitinib is an imported medicine. These two drugs are three generations of EGFR targeted drugs for lung cancer, so people will inevitably compare them directly. Look at the price first. Both drugs are covered by medical insurance. Who is cheaper? After entering medical insurance, the price of amitinib is 3520 yuan per box (55mg/ tablet), and the consumption of amitinib is 3 boxes per month, so the monthly cost is 10560 yuan. The latest medical insurance price of oxitinib has not been announced, and the previous price was 5 10 yuan (80mg/ tablet); 300 yuan (40mg/ tablet), according to the dosage of oxytinib, the minimum monthly cost of oxytinib is 15300 yuan. This time, when the medical insurance indications are extended to the medical insurance catalogue, the price of oxytinib will definitely drop, so we predict that the monthly cost of oxytinib and amitinib will be close. Ositinib has a wider coverage of medical insurance. From the medical insurance indications, oxitinib has expanded the medical insurance indications, covering first-line treatment and second-line treatment.
First-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (non-small cell lung cancer) with exon 19 deletion or exon 2 1(L858R) mutation; To treat adult patients with locally advanced or metastatic non-small cell lung cancer who developed diseases during or after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and were confirmed to have EGFR T790M mutation. In other words, patients with advanced non-small cell lung cancer with EGFR gene mutation can get medical insurance reimbursement whether they are treated with first-line or second-line oxitinib. Amitinib's medical insurance indication is second-line treatment. In the past, the disease progressed during or after treatment with tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), and adult patients with locally advanced or metastatic non-small cell lung cancer with positive mutation of EGFR T790M were confirmed. Within the scope of medical insurance, oxitinib is bigger and covers more lung cancer patients. At present, there is no clinical trial to directly compare the efficacy of these two drugs, but they have their own advantages. In clinical trials, the median progression-free survival time of patients with EGFR mutation and T790M positive advanced non-small cell lung cancer in China reached 12.3 months, making amitinib the first third-generation EGFR lung cancer targeted drug in the world with a median progression-free survival time exceeding 1 year, setting a record! However, in the first-line treatment, oxitinib has great advantages. At the annual meeting of the European Society of Oncology (ESMO) on 20 19, the research team announced the results of phase III clinical trials of first-line treatment of advanced lung cancer with oxitinib. The median progression-free survival (PFS) and median overall survival (OS) of patients in the oxitinib group were as long as 18.9 months and 38.6 months, which were the highest in clinical trials of lung cancer! Therefore, the first-line treatment of targeted therapy for EGFR lung cancer is oxitinib, and the second-line treatment is amitinib.